Effects of erythromycin on experimental extrinsic allergic alveolitis
- 1 February 1999
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 29 (2) , 253-261
- https://doi.org/10.1046/j.1365-2222.1999.00430.x
Abstract
Background: Recent clinical studies have demonstrated the efficacy of erythromycin for treating patients with chronic lower respiratory tract inflammation. Mechanisms related to the anti‐inflammatory action are yet to be determined.Objectives: The therapeutic efficacy of erythromycin in experimental extrinsic allergic alveolitis (EAA) was evaluated.Methods: A murine model of EAA was developed by intratracheal inoculations with particulate Trichosporon mucoides followed by erythromycin or josamycin treatment. Cell populations, specific antibodies, chemotactic activities, TNF‐α, IL‐1β, MIP‐2 and KC of bronchoalveolar lavage fluid (BALF); histopathology of the lung and footpad reaction; myeloperoxidase of the whole lung; and immunohistochemistry of intercellular adhesion molecule‐1 (ICAM‐1), at 6 and 96 h after the challenge, were examined.Results: There was a marked neutrophilic alveolitis and bronchiolitis at 6 h, and lymphocytic alveolitis and perivenule cuffing at 96 h after the challenge. Increase in total inflammatory cells and neutrophils in BALF at 6 h was significantly suppressed by pre‐treatment with 5 mg/kg/day of erythromycin intraperitoneally for 5 days (P < 0.01), with no apparent effect on specific antibodies, chemotactic activity or cytokines. Erythromycin also suppressed the Arthus‐type reaction in the footpad (P < 0.01). Histopathological studies revealed that erythromycin markedly decreased neutrophils in the lung and skin lesions and myeloperoxidase in the lung, simultaneously with inhibiting ICAM‐1 expression. The therapy has no remarkable effects on lymphocytes or 96 h response. Josamycin had no effects on the model.Conclusions: The therapeutic dosage of erythromycin significantly suppressed acute neutrophil influx into the lung, intradermal Arthus reaction and the expression of ICAM‐1 in the lesions of experimental EAA. Erythromycin may be effective for treating subjects with acute EAA.Keywords
This publication has 43 references indexed in Scilit:
- Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage (BAL) fluids of extrinsic allergic alveolitisClinical and Experimental Immunology, 1995
- The production of cytokines by polymorphonuclear neutrophilsImmunology Today, 1995
- Inhibition by Erythromycin of Superoxide Anion Production by Human Polymorphonuclear Leukocytes through the Action of Cyclic AMP-Dependent Protein KinaseRespiration, 1995
- Experimental Hypersensitivity Pneumonitis in Mice Induced byTrichosporon cutaneum: Histologic and Immunologic Features and Effect of in Vivo Depletion of T Cell SubsetsExperimental Lung Research, 1993
- Modulation of acute morphine tolerance by corticotropin- releasing factor and dynorphin a in the mouse spinal cordLife Sciences, 1992
- The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of miceJournal of Antimicrobial Chemotherapy, 1992
- Influences of roxithromycin on cell-mediated immune responsesLife Sciences, 1992
- Southwestern Internal Medicine Conference: Hypersensitivity PneumonitisThe Lancet Healthy Longevity, 1990
- Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat.Journal of Clinical Investigation, 1989
- Longitudinal course of extrinsic allergic alveolitis in pigeon breeders.Thorax, 1989